JP5458446B2 - Biomaterial storage method - Google Patents
Biomaterial storage method Download PDFInfo
- Publication number
- JP5458446B2 JP5458446B2 JP2012015449A JP2012015449A JP5458446B2 JP 5458446 B2 JP5458446 B2 JP 5458446B2 JP 2012015449 A JP2012015449 A JP 2012015449A JP 2012015449 A JP2012015449 A JP 2012015449A JP 5458446 B2 JP5458446 B2 JP 5458446B2
- Authority
- JP
- Japan
- Prior art keywords
- voltage
- biomaterial
- application
- experiment
- storage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
この発明は、血液、細胞、組織、及び臓器を含む、生体材料の保存方法に関する。 The present invention relates to a biomaterial storage method including blood, cells, tissues, and organs.
従来、微生物及び動物由来物の保存方法として、100Vないし5000Vの交流又は直流電圧を電極に印加して静電場雰囲気を形成し、−20℃〜−40℃でこの静電場雰囲気内におくことによる保存方法が開示されていた。これは、100V〜5000V、好ましくは100V〜3000Vの交流又は直流電圧の静電場雰囲気に保存することにより、微生物又は動物由来物が有する活性を不活化若しくは不活性化させることなく、又は死滅化させることなく保存することができる、とされるものである(例えば、特許文献1参照)。 Conventionally, as a method for preserving microorganisms and animal-derived materials, an electrostatic field atmosphere is formed by applying an AC or DC voltage of 100 V to 5000 V to the electrode, and the electrostatic field atmosphere is placed at −20 ° C. to −40 ° C. A storage method has been disclosed. This is done by inactivating or inactivating the activity of microorganisms or animal-derived substances by storing them in an electrostatic field atmosphere of AC or DC voltage of 100V to 5000V, preferably 100V to 3000V. It can be stored without any problem (see, for example, Patent Document 1).
しかしながら、従来の保存方法では、電流電圧のかけ方について、電流は交流、直流のいずれであってもよいとされ、100V、500V、1000V等といった各電圧値の他に、有効な電圧印加方法の特定はされていなかった。また上記従来の保存方法では、長期間の間自然に近い状態で、微生物又は動物由来物が有する活性を不活化若しくは不活性化させることなく、又は死滅化させることなく保存することに主眼を置いたものであった。このため、保存による酸化の抑制や細胞障害の軽減が十分にできるものとはいいきれなかった。 However, in the conventional storage method, regarding the method of applying the current voltage, the current may be either alternating current or direct current. In addition to each voltage value such as 100V, 500V, 1000V, etc., an effective voltage application method It was not specified. In addition, the above conventional storage method focuses on storing the activity of microorganisms or animal-derived materials without inactivation, inactivation, or death, in a state close to nature for a long period of time. It was. For this reason, it cannot be said that it is possible to sufficiently suppress oxidation and reduce cell damage due to storage.
上記課題を解決すべく、本発明では下記(1)ないし(2)の手段を採用するものとしている。すなわち、
(1)本発明の生体材料の保存方法は、冷蔵庫内に電圧印加板を設置し、生体材料を収容した収容器を前記電圧印加板の上に載置し、前記生体材料に対して交流電圧とマイナスの直流電圧とを同時にかけることで、電圧同時印加ステップを行いながら生体材料を凍結する生体材料の保存方法であって、前記交流電圧の設定値の絶対値よりも前記直流電圧の設定値の絶対値のほうが大きいことを特徴とする。
In order to solve the above problems, the present invention adopts the following means (1) to (2) . That is,
(1) In the biomaterial storage method of the present invention , a voltage application plate is installed in a refrigerator, a container containing the biomaterial is placed on the voltage application plate, and an AC voltage is applied to the biomaterial. And the negative DC voltage are applied simultaneously to the biological material storage method to freeze the biological material while performing the simultaneous voltage application step, wherein the setting value of the DC voltage is higher than the absolute value of the setting value of the AC voltage. The absolute value of is characterized by being larger .
(2)また、前記生体材料の保存方法において、電圧同時印加ステップが、生体材料の少なくとも周囲を囲む導電性金属からなる収容器に生体材料を収容し、前記収容器の外部の一面に、直流電圧と交流電圧とを重畳印加した電圧印加板を直接又は間接的に沿わせることで、生体材料を間接的に電圧印加するものであることが好ましい。 (2) In the biomaterial storage method, in the simultaneous voltage application step, the biomaterial is accommodated in a container made of a conductive metal surrounding at least the periphery of the biomaterial, and a direct current is applied to an outer surface of the container. It is preferable that the voltage is applied to the biomaterial indirectly by directly or indirectly following the voltage application plate on which the voltage and the alternating voltage are superimposed and applied.
上記構成を採用することで、保存中の生体材料Oの溶存酸素を不活性化させることで、より効果的な保存による酸化の抑制や細胞障害の軽減が達成される。 By adopting the above-described configuration, inactivation of dissolved oxygen in the biomaterial O during storage can be achieved, and more effective suppression of oxidation and reduction of cell damage can be achieved.
本発明の実施の形態について図面を参照して詳細に説明する。図1は、実施例1の生体材料Oの保存方法における、印加板2、収容器1及び電極の保存時の状態例を示す斜視説明図である。図2は、図1に示す実施例1の状態例に、更に保存庫4を含めた保存時の全体構成を示す正面視断面説明図である。図3は、実施例2の生体材料Oの保存方法における、印加板2、収容器1及び電極の保存時の状態例を示す斜視説明図である。図4は、図3に示す実施例2の状態例に、更に保存庫4を含めた保存時の全体構成を示す正面視断面説明図である。図5は、実施例3の生体材料Oの保存方法における保存時の(保存庫4を含む)全体構成を示す概念説明図である。図6ないし図9はそれぞれ、実験1ないし実験4によるデータを示す図である。具体的には、図6が、室温保存によるラット血清脂質過酸化反応の抑制に関する実験1のデータである。また、図7が、ヒト赤血球凍結における直流交流同時印加の優位性に関する実験2のデータであり、図8が、ヒト赤血球凍結における電圧印加の至適条件に関する実験3のデータであり、図9が、細胞培養による酸化ストレス下での細胞死の比較に関する実験4のデータである。 Embodiments of the present invention will be described in detail with reference to the drawings. FIG. 1 is an explanatory perspective view illustrating an example of a state when the application plate 2, the container 1 and the electrode are stored in the method for storing the biomaterial O according to the first embodiment. FIG. 2 is a front cross-sectional explanatory view showing the entire configuration during storage including the storage 4 in addition to the state example of the embodiment 1 shown in FIG. 1. FIG. 3 is a perspective explanatory view illustrating an example of a state of the application plate 2, the container 1, and the electrode during storage in the method for storing the biomaterial O according to the second embodiment. FIG. 4 is a front view cross-sectional explanatory diagram showing the overall configuration during storage including the storage 4 in addition to the state example of the embodiment 2 shown in FIG. 3. FIG. 5 is a conceptual explanatory diagram showing an overall configuration (including the storage 4) at the time of storage in the biomaterial O storage method of the third embodiment. 6 to 9 are diagrams showing data obtained in Experiments 1 to 4, respectively. Specifically, FIG. 6 is data of Experiment 1 regarding suppression of rat serum lipid peroxidation by storage at room temperature. 7 is data of Experiment 2 regarding the superiority of DC / AC simultaneous application in freezing of human erythrocytes, FIG. 8 is data of Experiment 3 regarding optimal conditions for voltage application in freezing of human erythrocytes, and FIG. The data of Experiment 4 regarding the comparison of cell death under oxidative stress by cell culture.
(「血液、細胞、組織、及び臓器の保存」という言葉の及ぶ範囲について)
「生体材料Oの保存」という言葉の及ぶ範囲に関し、本発明の「生体材料O」には、血液、細胞、組織、及び臓器のいずれもが含まれる。また、「生体材料Oの保存」という言葉の及ぶ範囲に関し、本発明の「保存」には次の3つの意味が含まれる。
(1)室温保存(4℃から20℃(室温))
(2)凍結保存(−20℃から−196℃(液体窒素の温度))
(3)細胞の培養保存(37℃)
後述する実験1(図6)は、ラットの血清を上記1)室温保存したものである。また実験2(図7)及び3(図8)は、ヒト赤血球の凍結保存である。なお、(実験2)と(実験3)は同じ実験であるが、(実験2)の方はα(交流)単独とβ(直流)単独及びαβ併用とを比較したもので、(実験3)は同時印加の至適条件を調べたものである。実験4(図9)は(3)の培養保存である。
(Regarding the scope of the term “preservation of blood, cells, tissues, and organs”)
Regarding the scope covered by the term “preservation of biomaterial O”, “biomaterial O” of the present invention includes blood, cells, tissues, and organs. In addition, regarding the range covered by the term “preservation of biomaterial O”, “preservation” of the present invention includes the following three meanings.
(1) Room temperature storage (4 ° C to 20 ° C (room temperature))
(2) Cryopreservation (-20 ° C to -196 ° C (temperature of liquid nitrogen))
(3) Cell culture preservation (37 ° C)
Experiment 1 (FIG. 6), which will be described later, is the above-described 1) room temperature storage of rat serum. Experiments 2 (FIG. 7) and 3 (FIG. 8) are cryopreservation of human erythrocytes. (Experiment 2) and (Experiment 3) are the same experiment, but (Experiment 2) is a comparison between α (alternating current) alone, β (direct current) alone and αβ combined, (experiment 3). Indicates the optimum conditions for simultaneous application. Experiment 4 (FIG. 9) is the culture preservation of (3).
本発明の実施例1の生体材料Oの保存方法は、生体材料Oに対して図1及び図2に示す保存装置によって、直流電圧と交流電圧とを同時に、すなわち重畳的にかける電圧同時印加ステップを含むことを特徴とする。この電圧同時印加ステップは、収容器1たるチューブスタンド型保持器に生体材料Oを収容し、前記収容器1の外部の一面に、直流電圧と交流電圧とを重畳印加した電圧印加板2上を直接接触させて沿わせることで、生体材料Oを間接的に電圧印加するものである。なお、収容器1と印加板2とを接触させず、印加板2を間接的に沿わせる保存状態でも良い。 The biomaterial O storage method according to the first embodiment of the present invention is a voltage simultaneous application step in which a DC voltage and an AC voltage are simultaneously applied to the biomaterial O by the storage device shown in FIGS. It is characterized by including. In this voltage simultaneous application step, the biomaterial O is accommodated in a tube stand type holder as the container 1, and the voltage application plate 2 on which a DC voltage and an AC voltage are superimposed and applied to the outer surface of the container 1 is applied. A voltage is applied to the biomaterial O indirectly by direct contact. A storage state in which the container 1 and the application plate 2 are not brought into contact with each other and the application plate 2 is indirectly aligned may be employed.
本発明の同時電圧印加を行う場合、例えば収容器1に直接電極を繋ぐことによる電圧印加や、生体材料Oを印加板2に直接載置することによる電圧印加よりも、前記のような間接的な電圧印加のほうが、効率的に、均等な電圧印加効果を得られることが判った。 When performing the simultaneous voltage application of the present invention, for example, the indirect as described above rather than the voltage application by directly connecting the electrode to the container 1 or the voltage application by directly placing the biomaterial O on the application plate 2. It was found that a uniform voltage application effect can be obtained efficiently by applying a proper voltage.
具体的には、電圧同時印加ステップは、直流電圧と交流電圧とを重畳印加した電圧印加板2上に、生体材料Oを入れた収容器1(実施例1の収容器1はチューブスタンド型保持器)を積置することによる。 Specifically, in the voltage simultaneous application step, a container 1 in which a biomaterial O is placed on a voltage application plate 2 on which a DC voltage and an AC voltage are superimposed and applied (the container 1 of Example 1 is a tube stand type holder). By placing a container).
(収容器1)
収容器1は、生体材料Oの少なくとも周囲を囲むようにして生体材料Oを収容する容器であり、導電性金属、特に高伝導性の金属を主成分としてなる。実施例1では、純度80%以上のアルミニウムを主成分とする金属からなる。具体的には、60mm厚さのアルミニウム板に、生体材料Oを収容するための収容穴1hを8個、所定の穴間隔を開けてくりぬいた、チューブスタンド型保持器である。
(Container 1)
The container 1 is a container that stores the biomaterial O so as to surround at least the periphery of the biomaterial O, and is mainly composed of a conductive metal, particularly a highly conductive metal. In Example 1, it consists of the metal which has aluminum of purity 80% or more as a main component. Specifically, it is a tube stand type holder in which an aluminum plate having a thickness of 60 mm is provided with eight accommodation holes 1h for accommodating the biomaterial O, with a predetermined hole interval.
(収容穴1h)
収容穴1hは、収容器1の少なくとも壁及び底(好ましくは更に蓋)に覆われて、収容した生体材料Oの、少なくとも周囲四方向及び下面方向(好ましくは更に上面)を囲うように構成される。但し、ここでいう底(或いは生体材料Oからみた下面方向)とは、電圧印加される印加板2をそわせる構成板をいう。
(Accommodating hole 1h)
The accommodation hole 1h is covered with at least the wall and the bottom (preferably further a lid) of the container 1, and is configured to surround at least the surrounding four directions and the lower surface direction (preferably the upper surface) of the accommodated biomaterial O. The However, the bottom here (or the lower surface direction seen from the biomaterial O) refers to a component plate that deflects the application plate 2 to which a voltage is applied.
収容穴1h内の生体材料Oからみたとき、間接的な電圧印加の作用する方向(下面方向)を導電板(底板)で覆い、かつ、少なくとも、同方向と逆の方向(上面方向)を除いた、すべての側面方)を導電板(四方に連なる壁板)で覆うこととなる。 When viewed from the biomaterial O in the accommodation hole 1h, the direction in which the indirect voltage is applied (lower surface direction) is covered with a conductive plate (bottom plate), and at least the direction opposite to the same direction (upper surface direction) is excluded. All side surfaces) are covered with a conductive plate (a wall plate connected in all directions).
実施例1の収容穴1hは、円柱状にくりぬいた円柱穴からなる。生体材料Oが血液の場合、この収容穴1hに、試験管に入れた血液を収容するか、或いは血液を直接収容する。収容穴1hは穴のいずれの深さにおける断面も等しいことが好ましい。 The accommodation hole 1h according to the first embodiment is a cylindrical hole hollowed into a cylindrical shape. When the biomaterial O is blood, the blood contained in the test tube is accommodated in the accommodation hole 1h or the blood is directly accommodated. The housing hole 1h preferably has the same cross section at any depth of the hole.
(壁厚及び底厚)
同時印加による効果のために、収容器1の構成材料の厚さは、10mm以上(少なくとも底厚10mm、壁厚15mm以上、好ましくは底厚、壁厚共に15mm程度)であることが好ましい。
(Wall thickness and bottom thickness)
Because of the effect of simultaneous application, the thickness of the constituent material of the container 1 is preferably 10 mm or more (at least a bottom thickness of 10 mm and a wall thickness of 15 mm or more, preferably about 15 mm for both the bottom thickness and the wall thickness).
実施例1では、平面視縦方向の最小壁厚1a(収容穴1h側端から収容器1の正面側面(又は背面側面)までの水平方向最小距離)が15mm、
平面視横方向の最小壁厚1b(収容穴1h側端から収容器1の右側面(又は左側面)までの水平方向最小距離)が30mm、
高さ方向の最小底厚1c(収容穴1h底から収容器1の底面までの鉛直方向最小距離)が15mm、
収容穴1h断面の代表長1d(円形の収容穴1h断面の径、方形の収容穴1h断面の長辺)が14mm、
収容穴1h間の最小壁厚1e(隣り合う第一の収容穴1h側端から、隣り合う第二の収容穴1h側端までの水平方向最小距離)が15mmである。
In Example 1, the minimum wall thickness 1a in the vertical direction in plan view (the horizontal minimum distance from the side end of the accommodation hole 1h to the front side surface (or the back side surface) of the container 1) is 15 mm,
The minimum wall thickness 1b in the horizontal direction in plan view (the horizontal minimum distance from the side end of the receiving hole 1h to the right side (or left side) of the container 1) is 30 mm,
Minimum height 1c in the height direction (vertical minimum distance from the bottom of the receiving hole 1h to the bottom of the container 1) is 15 mm,
The representative length 1d of the cross section of the accommodation hole 1h (the diameter of the cross section of the circular accommodation hole 1h, the long side of the cross section of the square accommodation hole 1h) is 14 mm,
The minimum wall thickness 1e between the receiving holes 1h (the minimum horizontal distance from the adjacent first receiving hole 1h side end to the adjacent second receiving hole 1h side end) is 15 mm.
(印加板2)
印加板2は、導電性材料からなる板であり、一対の電気配線3による電極をそれぞれ対称位置に配してなる。電気配線3は、直流及び交流共に共通配線3としてなり、電極もまた直流及び交流を共有するものとして配される。これにより、同時印加によって、交流電圧の一部が直流電圧に重畳的に変換され、交流電圧の設定値よりも実際の(生体材料Oへの)交流電圧の実効値が低くなり、その分、直流電圧の設定値よりも実際の(生体材料Oへの)直流電圧の実効値が高くなる。
(Apply plate 2)
The application plate 2 is a plate made of a conductive material, and is formed by arranging electrodes of a pair of electric wirings 3 at symmetrical positions. The electrical wiring 3 is a common wiring 3 for both direct current and alternating current, and the electrodes are also arranged to share direct current and alternating current. Thereby, by simultaneous application, a part of the AC voltage is converted into a DC voltage in a superimposed manner, and the actual value of the AC voltage (to the biomaterial O) is lower than the set value of the AC voltage. The effective value of the actual DC voltage (to the biomaterial O) is higher than the set value of the DC voltage.
印加電圧は、直流、交流いずれも5000Vを超えないことが好ましい。さらにいえば、交流電圧の設定値が500ないし2500V、直流電圧の設定値が200ないし1000Vであることが好ましい。また、直流電圧はマイナスであることが好ましく、さらに交流電圧の設定値よりも、直流電圧の設定値(の絶対値)のほうが大きいことが好ましい。 The applied voltage preferably does not exceed 5000 V for both direct current and alternating current. Furthermore, it is preferable that the set value of the AC voltage is 500 to 2500 V and the set value of the DC voltage is 200 to 1000 V. The DC voltage is preferably negative, and the set value (absolute value) of the DC voltage is preferably larger than the set value of the AC voltage.
また、交流と直流の各電圧値の組合せについて好ましくは、直流電圧の設定値が1000V程度又は3000V程度のとき、交流電圧の設定値が500ないし550V程度であることが好ましい。 In addition, it is preferable for the combination of AC and DC voltage values that the AC voltage set value is about 500 to 550 V when the DC voltage set value is about 1000 V or about 3000 V.
但し、上記及び本発明にいう設定値とは、交流又は直流いずれか単独で電圧をかけたときの、実際の生体材料Oへの実効値をいう。 However, the set value referred to above and in the present invention refers to an effective value for the actual biomaterial O when a voltage is applied independently of either alternating current or direct current.
(保存庫4)
印加板2は、図2に示すような、保存棚月の保存庫4のうえに載置し、この状態で生体材料Oを保存する。
(Storage 4)
The application plate 2 is placed on the storage 4 of the storage shelf month as shown in FIG. 2, and the biomaterial O is stored in this state.
実施例2では、電圧同時印加ステップとして、直流電圧と交流電圧とを重畳印加した電圧印加板2上に、生体材料Oを入れた底厚、壁厚共に15mmの収容器1(実施例2の収容器1は升型保持器)を積置することによる。実施例2の収容器1を用いた電圧の同時印加保存によれば、容積の比較的大きな生体材料Oであっても、その他の構成は実施例1と同様である。 In Example 2, as a voltage simultaneous application step, a container 1 (both of Example 2 in which the bottom thickness and wall thickness of biomaterial O are placed on a voltage application plate 2 on which a DC voltage and an AC voltage are superimposed and applied) The container 1 is by stacking a cage holder). According to the simultaneous application and storage of voltage using the container 1 of the second embodiment, the other configuration is the same as that of the first embodiment even for the biomaterial O having a relatively large volume.
実施例3では、実施例1と比較して、収容器1の代わりに所定の袋材厚以上の収容袋を用いている。但し収容袋の内面には、導電性材料が塗布或いはラミネートされており、生体材料Oとほぼ全方向で接触することで、同時印加による効果を効率的に得るものとしている。生体材料Oには、図のAで示す直流電圧によるイオン誘引方向と、Bの矢印で示す交流電圧によるイオン誘引方向とが重畳的にかかる。 In the third embodiment, as compared with the first embodiment, a storage bag having a predetermined bag material thickness or more is used instead of the storage container 1. However, a conductive material is applied or laminated on the inner surface of the storage bag, and the effect of simultaneous application is obtained efficiently by contacting the biomaterial O in almost all directions. The biomaterial O is superimposed on the ion attraction direction by the DC voltage indicated by A in the figure and the ion attraction direction by the AC voltage indicated by the arrow B.
上記各実施例は、本発明の保存方法を達成するための例に過ぎず、必ずしも上記構成に限定されるものではなく、本発明の趣旨を逸脱しない範囲で種々の変形が可能である。 Each of the above-described embodiments is merely an example for achieving the storage method of the present invention, and is not necessarily limited to the above-described configuration, and various modifications can be made without departing from the spirit of the present invention.
(実験1「電圧印加によるラット血清脂質過酸化反応の抑制」(図6))
実験1として、ラットの血清を室温保存し、過酸化脂質量を測定した。
(Experiment 1 “Inhibition of Rat Serum Lipid Peroxidation by Applying Voltage” (FIG. 6))
In Experiment 1, rat serum was stored at room temperature and the amount of lipid peroxide was measured.
(実験1の実験方法)
ラット末梢血より血清を分離し、試料とした。試料をチューブに分注し、室温(20度)にて12時間静置、保存した。この際に印加板にα(交流)2020V、β(直流)3000Vの電圧を印加し、試料を印加板の上で印加しつつ保存した。12時間の保存の後、TBARS法(チオバルビツール酸反応物質法)を用いて過酸化脂質量を測定し、印加していない試料と比較した。TBARS法での測定では、試料中の過酸化脂質が分解してできるマロンジアルデヒド(MDA)がチオバルビツール酸と反応して赤色反応物をつくることを利用し、分光光度計にてその吸光度(525nm)を測定する。測定ではPharmacia Biotech社製Ultrospec 3000を用いて吸光度を測定し、その吸光度をもってそれぞれの群間で比較した。
(Experiment method of Experiment 1)
Serum was isolated from rat peripheral blood and used as a sample. The sample was dispensed into a tube and left to stand at room temperature (20 degrees) for 12 hours for storage. At this time, voltages of α (alternating current) 2020 V and β (direct current) 3000 V were applied to the application plate, and the sample was stored while being applied on the application plate. After storage for 12 hours, the amount of lipid peroxide was measured using the TBARS method (thiobarbituric acid reactant method) and compared with a sample that had not been applied. In the measurement by the TBARS method, malondialdehyde (MDA) produced by decomposition of lipid peroxide in a sample reacts with thiobarbituric acid to produce a red reactant, and its absorbance is measured with a spectrophotometer. (525 nm) is measured. In the measurement, absorbance was measured using an Ultraspec 3000 manufactured by Pharmacia Biotech, and the absorbance was compared between the groups.
(実験1の結果)
交流直流の電圧を印加した試料中の過酸化脂質量は、印加していない試料と比較して有意に吸光度が低く、過酸化脂質の産生が抑制されていることが示された。
(Result of Experiment 1)
The amount of lipid peroxide in the sample to which an AC / DC voltage was applied was significantly lower in absorbance than the sample to which no voltage was applied, indicating that production of lipid peroxide was suppressed.
このことは、電圧印加によって、血清中の脂質の酸化が抑制されていることを示している。 This has shown that the oxidation of the lipid in serum is suppressed by voltage application.
(実験2)「ヒト赤血球凍結における交流直流同時印加の優位性」(Effects of NICE01 Electric Deviceon RBC Cryopreservation(NICE01とは、本願発明の実施例1の保存装置を示す)と題された図7参照)
(実験2の実験方法)
ボランティアより採血して得られたヒト末梢血洗浄赤血球に凍結保存液(アルブミン加CP−1、極東製薬社)を等量添加した後に、−20度で3時間かけて凍結した。この際に冷凍庫内にアルミニウム製印加板を設置し、本発明の実施例1の電圧印加保存装置を用い、交流電圧(α5:980V)のみの単独印加、直流電圧(β8:3000V)のみの単独印加、交流直流同時(重畳)印加(α5β8)の3群それぞれについて電場を作製し、印加板の上で凍結を行なった。
(Experiment 2) “Advantage of AC / DC simultaneous application in human erythrocyte freezing” (see FIG. 7 entitled “Effects of NICE01 Electric Device RBC Cryopreservation”
(Experiment method of Experiment 2)
After adding an equal amount of cryopreservation solution (albumin-added CP-1, Far East Pharmaceutical Co., Ltd.) to human peripheral blood washed erythrocytes obtained by collecting blood from volunteers, the mixture was frozen at −20 ° C. for 3 hours. At this time, an aluminum application plate was installed in the freezer, and the voltage application storage device of Example 1 of the present invention was used, and the AC voltage (α5: 980 V) alone was applied alone, and the DC voltage (β8: 3000 V) alone was used. Electric fields were created for each of the three groups of application and AC / DC simultaneous (superimposed) application (α5β8), and the electric field was frozen on the application plate.
凍結サンプルはその後−80度のフリーザー内で2週間保存し、37度恒温槽にて解凍の後、遠心分離を行い、その上清中のLDH(乳酸脱水素酵素)量を測定した。LDH測定はPromega社製のLDH release assay kitを用いて測定し、吸光度はMolecular Devices社製のTERMO MAX microplate readerを用いて測定した。測定結果を、交流電圧(α5:980V)単独印加、直流電圧(β8:3000V)単独印加、及び交流直流同時(重畳)印加(α5β8)の3群間で比較した。 The frozen sample was then stored for 2 weeks in a -80 degree freezer, thawed in a 37 degree constant temperature bath, centrifuged, and the amount of LDH (lactate dehydrogenase) in the supernatant was measured. The LDH measurement was performed using an LDH release assay kit manufactured by Promega, and the absorbance was measured using a TERMO MAX microplate reader manufactured by Molecular Devices. The measurement results were compared between the three groups of AC voltage (α5: 980V) single application, DC voltage (β8: 3000V) single application, and AC / DC simultaneous (superposition) application (α5β8).
(実験2の結果)
凍結解凍後に末梢血赤血球より逸脱したLDHは、交流単独、直流単独また交流直流併用群のいずれの群においても電圧印加(−)よりも減少しており、細胞障害が少ないことが示された。また、交流直流併用において、交流単独、また直流単独よりも有意に細胞障害の低下が認められた。
この結果より、電圧印加凍結における細胞障害の軽減はα及びβの両者を同時印加した際に、より顕著にみられることが確認された。
(Result of Experiment 2)
LDH deviated from peripheral blood erythrocytes after freezing and thawing decreased in all groups of alternating current alone, direct current alone, or alternating current direct current combined group as compared with voltage application (-), indicating that cell damage was small. In addition, in AC / DC combination, a significant decrease in cell damage was observed compared to AC alone or DC alone.
From this result, it was confirmed that the reduction of cell damage in voltage application freezing was more noticeable when both α and β were applied simultaneously.
(実験3:「ヒト赤血球凍結における電圧印加の至適条件」(図8))
(実験3の実験方法)
実験2と同様、ボランティアより採血して得られたヒト末梢血洗浄赤血球に凍結保存液(アルブミン加CP−1、極東製薬社)を等量添加した後に、−20度で3時間かけて凍結した。この際に冷凍庫内にアルミニウム製印加板を設置し、本発明の実施例1の電圧印加保存装置を用い、表1に示す交流電圧(α)と、表2に示す直流電圧(β)の両者を印加し電場を作製し、印加板の上で凍結を行なった。電圧印加はαとβをそれぞれ、図8に示す組合せで行った。
(Experiment 3: “Optimum Conditions for Voltage Application in Freezing Human Red Blood Cells” (FIG. 8))
(Experiment method of Experiment 3)
As in Experiment 2, after adding an equal amount of cryopreservation solution (albumin-added CP-1, Far East Pharmaceutical Co., Ltd.) to human peripheral blood washed erythrocytes obtained by collecting blood from volunteers, it was frozen at −20 ° C. for 3 hours. . At this time, an aluminum application plate was installed in the freezer, and both the AC voltage (α) shown in Table 1 and the DC voltage (β) shown in Table 2 were used using the voltage application storage device of Example 1 of the present invention. Was applied to create an electric field and frozen on the application plate. The voltage application was performed in the combinations shown in FIG. 8 for α and β.
(実験3の結果)図8に実験3の結果を示す。図8では、各α(交流電圧)β(直流電圧)の組合せにおけるLDH量を、電圧印加していないもの(左側の色の薄いグラフ)と、電圧印加したもの(右側の色の濃いグラフ)とをそれぞれ並べて2本ずつ示す。図8では、Y軸(縦軸)の目盛りは吸光度の実測値を示す。値が大きいほど、壊れた赤血球の細胞内から遊離される酵素(LDH)の量が増えていて、細胞障害の程度が大きいということになる。吸光度自体は、測定時の温度条件などで実験ごとに値は変わるため、必ずコントロールすなわち電圧印加していないもの(図8の2本の各並列グラフの左側)と、電圧印加したもの(図8の2本の各並列グラフの右側)との二つを各実験ごとに同時に行い、それを比較することで印加の効果があるかどうかを検討した。図8のそれぞれの2本並列グラフでみるとNICE(−)(電圧印加していないもの)とNICE(+)(電圧印加したもの)の差が大きいほど印加の効果が大きいということになる。 (Results of Experiment 3) FIG. 8 shows the results of Experiment 3. In FIG. 8, the LDH amount in each combination of α (AC voltage) β (DC voltage) is not applied with voltage (light-colored graph on the left side) and applied with voltage (dark graph on the right-hand side). Two are shown side by side. In FIG. 8, the scale on the Y-axis (vertical axis) indicates the measured value of absorbance. The larger the value, the greater the amount of enzyme (LDH) released from the broken erythrocyte cell, and the greater the degree of cell damage. The absorbance itself varies depending on the experiment depending on the temperature conditions at the time of measurement. Therefore, the control, that is, the voltage is not applied (left side of the two parallel graphs in FIG. 8) and the voltage is applied (FIG. 8). The right side of each of the two parallel graphs was performed simultaneously for each experiment, and by comparing them, it was examined whether there was an application effect. In each of the two parallel graphs in FIG. 8, the larger the difference between NICE (−) (without voltage application) and NICE (+) (with voltage application), the greater the effect of application.
凍結解凍後に末梢血赤血球より逸脱したLDHは、α(交流)、β(直流)の、いずれの組合せにおいても印加をかけない群に比較して減少しており、凍結時の赤血球傷害が印加によって抑制されていることが示された。また特に、α5(980V)β8(3000V)、α5(980V)β3(950V)、α3(530V)β8(3000V)の組合せにて、より強い遊離LDHの減少が認められた。 LDH deviated from peripheral blood erythrocytes after freezing and thawing is decreased compared to the group to which no application is applied in any combination of α (alternating current) and β (direct current). It was shown to be suppressed. In particular, the combination of α5 (980 V) β8 (3000 V), α5 (980 V) β3 (950 V), and α3 (530 V) β8 (3000 V) showed a stronger decrease in free LDH.
(実験4「電圧印加による酸化ストレス下での細胞障害抑制」(図9))
実験4として、過酸化水素を細胞培養に添加して細胞障害を誘導し、これによる細胞死の比較実験を行った。
(Experiment 4 “Inhibition of cell damage under oxidative stress by applying voltage” (FIG. 9))
As Experiment 4, hydrogen peroxide was added to the cell culture to induce cell damage, and a comparative experiment of cell death was performed.
(実験目的)
ナイスゼロワンでの電圧同時印加が、生きた細胞に与える影響及び参加ストレス軽減に及ぼす影響を調べるため、培養細胞に過酸化水素による酸化ストレスを与えた状態での電圧印加の効果について検証した。
(Experimental purpose)
In order to investigate the effect of simultaneous voltage application with Nice Zero One on living cells and the effect of reducing participation stress, the effect of voltage application in a state in which oxidative stress due to hydrogen peroxide was applied to cultured cells was examined.
(実験方法)
ヒトマクロファージ細胞株であるTHP−1細胞を、96穴培養プレートを用いて、RPMI1640培養液中で37℃、5%CO2存在下で12時間培養し、その際に0uMから250uMの過酸化水素を添加し、酸化ストレスによる細胞障害を誘導した。培養器はナプコ社製インキュベーターを用い、この培養庫内にアルミニウム製印加板を設置し、この印加板の上に96穴培養プレートを静置し、交流電圧及び直流電圧の同時印加(α5β8)の下に培養を行った。細胞傷害の評価はMTT法を用いた。細胞培養開始12時間後にMTT試薬(5mg/ml)を培養プレートの各ウェルに20ul/ウェルずつ添加し、さらに4時間培養。全培養終了後SDS試薬を各ウェルに加えて細胞を溶解させた後に、ミトコンドリア内の脱水素酵素にて還元されて生成したフォルマザンを吸光度プレートリーダー(Molecular Devices社製のTERMO MAX microplate reader)を用いて波長490nmにて吸光度を測定した。
(experimental method)
THP-1 cells, a human macrophage cell line, were cultured in a RPMI1640 culture medium at 37 ° C. in the presence of 5% CO 2 for 12 hours using a 96-well culture plate. At that time, 0 uM to 250 uM hydrogen peroxide was added. Added to induce cell damage due to oxidative stress. The incubator is an incubator manufactured by Napco, an aluminum application plate is installed in the incubator, a 96-well culture plate is placed on the application plate, and AC voltage and DC voltage are simultaneously applied (α5β8). The culture was performed below. The MTT method was used for evaluation of cell injury. 12 hours after the start of cell culture, 20 ul / well of MTT reagent (5 mg / ml) was added to each well of the culture plate, and further cultured for 4 hours. After completion of the entire culture, SDS reagent was added to each well to lyse the cells, and then the formazan reduced by dehydrogenase in mitochondria was produced using an absorbance plate reader (TERMO MAX microplate reader manufactured by Molecular Devices). The absorbance was measured at a wavelength of 490 nm.
(実験4の結果(図9))過酸化水素添加による細胞のviabilityへの影響は、100uMまでの低い濃度では細胞のviabilityを上げ、逆に高い濃度では細胞死を誘導する。本実験でもMTT法での吸光度値は低濃度にてやや上昇し、高濃度にて低下していた。電圧印加群では印加(−)に比べて、いずれの過酸化水素濃度においても吸光度値が高く、細胞のviabilityが上昇または維持されていた。 (Results of Experiment 4 (FIG. 9)) The effect of hydrogen peroxide addition on cell viability increases cell viability at low concentrations up to 100 uM, and conversely induces cell death at high concentrations. Also in this experiment, the absorbance value by the MTT method slightly increased at a low concentration and decreased at a high concentration. In the voltage application group, the absorbance value was higher at any hydrogen peroxide concentration than in the application (-), and the viability of the cells was increased or maintained.
実験ではMTT法をもちいて細胞のviabilityを測定しているが、吸光度の値が大きいほどviabilityが高く、逆に値が低いと生きた細胞は少ないということになる。ここで、一般的に細胞は、低い濃度の酸化ストレスを細胞増殖等の刺激として活用するが、病的な高いレベルの酸化ストレスは細胞障害また細胞死を誘導する。このため、100uMまでの低い濃度では細胞のviabilityは逆に少し上がる一方、250uMの高い濃度では細胞は傷害を受けて吸光度は下がる。結果として、電圧印加を行うと高い濃度の酸化ストレスでも細胞が死ににくくなるということがいえる。 In the experiment, the viability of the cells is measured using the MTT method. However, the greater the absorbance value, the higher the viability, and conversely, the lower the value, the fewer live cells. Here, cells generally use a low concentration of oxidative stress as a stimulus for cell proliferation or the like, but a pathologically high level of oxidative stress induces cell damage or cell death. For this reason, the viability of the cell is slightly increased at a low concentration up to 100 uM, while the cell is damaged and the absorbance is decreased at a high concentration of 250 uM. As a result, it can be said that when a voltage is applied, cells are less likely to die even at a high concentration of oxidative stress.
この現象の説明としては、実験1(図6)にあるように電圧印加による酸化反応の中和、抑制が挙げらるが、それ以外にも電気エネルギーが生物エネルギーに変換されているという新たなメカニズムがあると思われる。すなわち、細胞が死なないようにするためには、細胞内のエネルギー(ATP)を増やしてやることが大事であるが、電圧印加をかけることで細胞が死ににくくなると考えられる。 As an explanation of this phenomenon, as shown in Experiment 1 (FIG. 6), the neutralization and suppression of the oxidation reaction by applying a voltage can be mentioned, but in addition, a new that electrical energy is converted into biological energy. There seems to be a mechanism. That is, in order to prevent the cells from dying, it is important to increase the energy (ATP) in the cells, but it is considered that the cells are difficult to die by applying a voltage.
(血液の冷凍保存の具体的な手順例)
血液の冷凍保存の具体的な手順例は、次のようなものである。供血者の肘静脈穿刺にて約400mlの末梢血を採血し、貯血バッグに保存する。遠心機にて血漿成分と血球成分とに分離後、血漿成分を除去し、生理食塩水および凍結保護液(CP−1、極東製薬工業社製)を加え凍結保存する。この際にα(交流)、β(直流)の同時印加を行いつつ凍結する。
(Specific procedure for frozen storage of blood)
Specific examples of procedures for cryopreserving blood are as follows. Approximately 400 ml of peripheral blood is collected by puncture of the donor's elbow vein and stored in a blood storage bag. After the plasma component and blood cell component are separated by a centrifuge, the plasma component is removed, and physiological saline and a cryoprotectant (CP-1, manufactured by Kyokuto Pharmaceutical Co., Ltd.) are added and stored frozen. At this time, freezing is performed while simultaneously applying α (alternating current) and β (direct current).
医療産業で考えられる本発明の同時印加技術の利用可能性には下記のものがある。先ず電圧印加での凍結保存として、輸血用同種末梢血凍結保存、自己血液凍結保存、骨髄移植用骨髄細胞凍結保存、臍帯血凍結保存、膵島細胞凍結保存、各種培養細胞凍結保存、ES細胞凍結保存、移植用各種臓器の凍結保存、そして、骨、大動脈、気管、心臓弁、角膜、皮膚等の組織移植片の凍結保存が挙げられる。 Applicability of the simultaneous application technique of the present invention considered in the medical industry includes the following. First, cryopreservation by voltage application: allogeneic peripheral blood cryopreservation for blood transfusion, autologous blood cryopreservation, bone marrow transplant bone marrow cryopreservation, cord blood cryopreservation, islet cell cryopreservation, various cultured cell cryopreservation, ES cell cryopreservation And cryopreservation of various organs for transplantation, and cryopreservation of tissue grafts such as bone, aorta, trachea, heart valve, cornea, and skin.
次に、電圧印加での冷保存として、輸血用同種末梢血保存、自己血液保存、移植用各種臓器の冷保存が挙げられる。 Next, examples of cold storage by applying voltage include allogeneic peripheral blood storage for blood transfusion, autologous blood storage, and cold storage of various organs for transplantation.
1 収容器
11 チューブスタンド型収容器
12 升型収容器
1h 収容穴
1a 平面視縦方向の最小壁厚(収容穴側端から収容器の正面側面(又は背面側面)までの水平方向最小距離)
1b 平面視横方向の最小壁厚(収容穴側端から収容器の右側面(又は左側面)までの水平方向最小距離)
1c 高さ方向の最小底厚(収容穴底から収容器の底面までの鉛直方向最小距離)
1d 収容穴断面の代表長(円形の収容穴断面の径、方形の収容穴断面の長辺)
1e 収容穴間の最小壁厚(隣り合う第一の収容穴側端から、隣り合う第二の収容穴側端までの水平方向最小距離)
2 電圧印加板
3 電気配線
4 保存庫
41 保存棚
5 収容袋
O 生体材料
DESCRIPTION OF SYMBOLS 1 Container 11 Tube stand type | mold container 12 Vertical type container 1h Housing hole 1a The minimum wall thickness of the vertical direction of planar view (horizontal direction minimum distance from a housing hole side end to the front side surface (or back side surface) of a container)
1b Minimum wall thickness in the horizontal direction in plan view (horizontal minimum distance from the side of the receiving hole to the right side (or left side) of the container)
1c Minimum bottom thickness in the height direction (vertical minimum distance from the bottom of the receiving hole to the bottom of the container)
1d Representative length of cross section of receiving hole (diameter of circular receiving hole cross section, long side of rectangular receiving hole cross section)
1e Minimum wall thickness between receiving holes (horizontal minimum distance from adjacent first receiving hole side end to adjacent second receiving hole side end)
2 Voltage application plate 3 Electrical wiring 4 Storage box 41 Storage shelf 5 Storage bag O Biomaterial
Claims (3)
前記電圧印加板に設定値530V〜980Vの交流電圧と、設定値−950V〜−3000Vの直流電圧とを同時にかけることで、電圧同時印加ステップを行いながら生体材料を凍結することを特徴とする生体材料の保存方法。 A voltage application plate is installed in the refrigerator, and a container containing a biomaterial is placed on the voltage application plate,
The biological material is frozen while performing the voltage simultaneous application step by simultaneously applying an AC voltage of a set value of 530 V to 980 V and a DC voltage of a set value of -950 V to -3000 V to the voltage application plate. Material storage method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012015449A JP5458446B2 (en) | 2012-01-27 | 2012-01-27 | Biomaterial storage method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012015449A JP5458446B2 (en) | 2012-01-27 | 2012-01-27 | Biomaterial storage method |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005380715A Division JP4965125B2 (en) | 2005-12-31 | 2005-12-31 | Biomaterial storage method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012077096A JP2012077096A (en) | 2012-04-19 |
| JP5458446B2 true JP5458446B2 (en) | 2014-04-02 |
Family
ID=46237729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012015449A Expired - Fee Related JP5458446B2 (en) | 2012-01-27 | 2012-01-27 | Biomaterial storage method |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5458446B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7218483B2 (en) * | 2018-03-21 | 2023-02-07 | 土佐電子工業株式会社 | A method for producing drinking water, conditioned water or functional water, and an apparatus for producing drinking water, conditioned water or functional water. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3862085B2 (en) * | 2003-09-19 | 2006-12-27 | メビックス株式会社 | Preservation method of microorganisms and animal-derived materials |
| JP4965125B2 (en) * | 2005-12-31 | 2012-07-04 | 国立大学法人高知大学 | Biomaterial storage method |
-
2012
- 2012-01-27 JP JP2012015449A patent/JP5458446B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012077096A (en) | 2012-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2663793C2 (en) | Trehalose and dextran-containing solution for transplanting mammalian cells | |
| JP7382602B2 (en) | Compositions, cell preservation compositions, cell culture compositions, cell preparations, methods for producing objects containing microbubbles, methods for preserving cells, methods for culturing cells, and methods for producing cell preparations | |
| US8198085B2 (en) | Somatic cells for use in cell therapy | |
| WO2009120996A1 (en) | Mehtod, system, and apparatus for hypothermic collection, storage, transport and banking of birth tissue | |
| JP2009513235A (en) | Compositions and methods for the assessment and resuscitation of cadaveric hearts for transplantation | |
| Ma et al. | Umbilical cord blood cell transplantation for myocardial regeneration | |
| JP2009007296A (en) | Biomaterial storage method | |
| JP4965125B2 (en) | Biomaterial storage method | |
| JP5458446B2 (en) | Biomaterial storage method | |
| JP2015174823A (en) | Biomaterial storage method, biomaterial production method, biomaterial, transplant material, transplant method, and biomaterial storage apparatus | |
| JP3862085B2 (en) | Preservation method of microorganisms and animal-derived materials | |
| JPWO2019230973A1 (en) | Biomaterial Preservation Compositions, Biomaterial Preservation Methods, Biomaterial Production Methods, Transplant Materials, and Transplant Methods | |
| CN110028571A (en) | The preparation method and applications of blood broken wall growth factor | |
| Berz et al. | Cryopreservation of hematopoietic and non-hematopoietic stem cells–a review for the clinician | |
| JP7546968B2 (en) | How to preserve cells | |
| Roura et al. | Quality and exploitation of umbilical cord blood for cell therapy: are we beyond our capabilities? | |
| CN114557336B (en) | Tissue treatment fluid capable of improving primary separation quantity and activity of tissues as well as preparation method and application thereof | |
| WO2006100740A1 (en) | Method for storage of substances originated from microorganism and animal | |
| JP2007295802A (en) | Preservation method of microorganisms and animal-derived materials | |
| JP2013223504A (en) | Inhibitor of reduction of cell survival rate | |
| Arif et al. | Senescent profile of cryopreserved adipose mesenchymal stem cells after multiple passages | |
| JP2022533949A (en) | Packaging and transport of high concentration cells | |
| US20170258075A1 (en) | Apparatus and method for storing tissue | |
| US20210317415A1 (en) | Perfusion system for harvesting bone marrow | |
| RU2782185C1 (en) | Additional solution for storing washed defrosted erythrocytes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120220 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130110 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130524 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130605 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130802 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130918 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131024 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131112 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131204 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131227 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5458446 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |